Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene (original) (raw)

Leukemia volume 18, pages 1020–1021 (2004)Cite this article

TO THE EDITOR

Imatinib (Glivec®) induces major cytogenetic responses in the vast majority of newly diagnosed CML patients. Most of these responses are durable, but a minority of patients progress to accelerated phase and eventually to blast crisis. Mechanisms causing this secondary resistance have been described and include mutations in the ATP binding site of Abl and amplification of genomic Bcr-Abl.1 Here, we describe a CML patient who showed a remarkable clinical course on imatinib, developing blast crisis after having been in a complete cytogenetic response for more than 2 years. The bcr-abl transcript was aberrant, showing an insert of a ‘kringle’ domain of the Kremen-1 gene, which, to the best of our knowledge, has not been reported before.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1

References

  1. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
    Article CAS Google Scholar
  2. Cross NC, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186–189.
    CAS Google Scholar
  3. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002; 417: 664–667.
    Article CAS Google Scholar
  4. Nakamura T, Aoki S, Kitajima K, Takahashi T, Matsumoto K, Nakamura T . Molecular cloning and characterization of Kremen, a novel kringle-containing transmembrane protein. Biochim Biophys Acta 2001; 1518: 63–72.
    Article CAS Google Scholar
  5. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461–463.
    Article CAS Google Scholar
  6. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392–2400.
    Article Google Scholar
  7. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119.
    Article CAS Google Scholar
  8. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212.
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, VU University Medical Center, de Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
    J J W M Janssen, J W van Oostveen, Q Waisfisz, G J Schuurhuis & G J Ossenkoppele
  2. III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany
    A Hochhaus

Authors

  1. J J W M Janssen
    You can also search for this author inPubMed Google Scholar
  2. A Hochhaus
    You can also search for this author inPubMed Google Scholar
  3. J W van Oostveen
    You can also search for this author inPubMed Google Scholar
  4. Q Waisfisz
    You can also search for this author inPubMed Google Scholar
  5. G J Schuurhuis
    You can also search for this author inPubMed Google Scholar
  6. G J Ossenkoppele
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJ J W M Janssen.

Rights and permissions

About this article

Cite this article

Janssen, J., Hochhaus, A., van Oostveen, J. et al. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.Leukemia 18, 1020–1021 (2004). https://doi.org/10.1038/sj.leu.2403338

Download citation

This article is cited by